Bio-Techne (TECH) has received a new Buy rating, initiated by Evercore ISI analyst, Vijay Kumar.
Vijay Kumar has given his Buy rating due to a combination of factors that highlight Bio-Techne’s strong market position and growth potential. The company is recognized as a premium growth asset with substantial revenue and impressive operational margins, which are among the best in its class. Bio-Techne’s core business, which includes proteins, antibodies, and reagents, is complemented by promising growth verticals such as cell and gene therapy, proteomic analytical instruments, spatial biology, and precision diagnostic tools. These elements are expected to drive the company’s sustainable growth significantly above the market average, with an anticipated acceleration in the coming years.
Despite potential short-term challenges from macroeconomic factors affecting academic markets, Kumar believes that the market’s reaction to these headwinds is exaggerated. He anticipates that Bio-Techne will effectively navigate these challenges, drawing a parallel to the strategic agility described in the ‘5 Ds’ approach. This perceived overreaction presents a favorable entry point for investors as the end markets recover and the company’s strong operational metrics come into play, supporting the Outperform rating with a target price of $75.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TECH in relation to earlier this year.
Questions or Comments about the article? Write to editor@tipranks.com